All In Biotech

Drug Trial Radar · NCT04971733

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Jun 28, 2021

Primary completion

May 24, 2024

Study completion May 24, 2024

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.

Conditions

  • Alzheimer Disease

Interventions

  • E2814Drug

    E2814 intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From first dose of study drug up to 120 weeks
  2. Number of Participants With Markedly Abnormal Laboratory ValuesTime frame: From first dose of study drug up to 120 weeks
  3. Number of Participants With Clinically Significant Change in Vital Signs ValuesTime frame: From first dose of study drug up to 120 weeks
  4. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) FindingsTime frame: From first dose of study drug up to 120 weeks
  5. Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 WeeksTime frame: Pre-dose at Week 12

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • UC San Diego Altman Clinical and Translational Research Insititute Clinic

    La Jolla, California

  • Indiana University School of Medicine, Health Partners, Adult Neurology Clinic

    Indianapolis, Indiana

  • National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.